TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer

Helsinki, Finland – 14 June 2021: TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer. The trial will evaluate the company’s adenoviral cancer immunotherapy TILT-123, a double cytokine armed oncolytic adenovirus, in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in a dose escalation trial in platinum resistant or refractory ovarian cancer patients.

Read full release here